eptinezumab
Jump to navigation
Jump to search
Indications
- prevention of chronic migraine
- abortive therapy* for migraine[3]
* fesibility of admnistering IV infusion during migraine attack may be an issue[3]
Dosage
- 300 mg IV infusion every 3 months
Adverse effects
Mechanism of action
- humanized IgG1 monoclonal antibody
- CGRP receptor antagonist
More general terms
References
- ↑ George J. Eptinezumab Effective in Chronic Migraine. Intravenous CGRP blocker shows rapid treatment effect. MedPage Today. April 27, 2018 https://www.medpagetoday.com/meetingcoverage/aan/72586
Lipton R, et al A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of eptinezumab for the preventive treatment of chronic migraine: Results of the PROMISE-2 Trial. American Academy of Neurology (AAN) 2018.
Lipton R, et al Increased migraine-free intervals with eptinuzumab were associated with improved health-related quality-of-life outcomes through week 12: Results from the phase 3 PROMISE-1 Trial. American Academy of Neurology (AAN) 2018.
Egilius L et al Repeat infusions of eptinezumab associated with greater migraine reductions and longer migraine-free intervals: Results from the Phase 3 PROMISE-1 Trial. American Academy of Neurology (AAN) 2018. - ↑ Ashina M, Saper J, Cady R et al Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia. 2020 Mar;40(3):241-254. PMID: https://www.ncbi.nlm.nih.gov/pubmed/32075406 PMCID: PMC7066477 Free PMC article
- ↑ 3.0 3.1 3.2 Winner PK, McAllister P, Chakhava G et al Effects of Intravenous Eptinezumab vs Placebo on Headache Pain and Most Bothersome Symptom When Initiated During a Migraine Attack. A Randomized Clinical Trial. JAMA. 2021;325(23):2348-2356. June 15 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34128999 PMCID: PMC8207242 (available on 2021-12-15) https://jamanetwork.com/journals/jama/fullarticle/2781053
Burch R, Rayhill M Acute Treatment for Migraine. Contemporary Treatments and Future Directions. JAMA. 2021;325(23):2346-2347. June 15 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34129013 https://jamanetwork.com/journals/jama/fullarticle/2781072